Home Addressing standardized definitions of post-COVID and long-COVID
Article Publicly Available

Addressing standardized definitions of post-COVID and long-COVID

  • Giuseppe Lippi ORCID logo EMAIL logo , Brandon M. Henry , Julien Favresse and Mario Plebani ORCID logo
Published/Copyright: April 25, 2023

Although the clinical burden of coronavirus disease 2019 (COVID-19) has undergone a substantial decline over time [1], the consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections remain substantial worldwide, persuading the World Health Organization (WHO) to reiterate the status of public health emergency of international concern [2]. Besides the still important clinical burden of an acute infection, especially in the most vulnerable parts of the general population, several concerns have emerged regarding the medium- and long-term impact on health and fitness, a still vague syndromic condition that is shared by many viral infections and may involve between 9 and 63 % of all COVID-19 patients [3], especially those who experienced more severe COVID-19 illness (e.g., hospitalized or needing intensive care), patients with underlying health conditions and who did not receive COVID-19 vaccination.

There is still large confusion and open debate as to what should be defined as a “pathological continuum of symptoms after recovering from an acute SARS-CoV-2 infection”, including confusion over appropriate terminology, such as differentiating between “post-COVID” and “long-COVID” (notably, other terminology could be used, including “long-haul COVID”, “post-acute COVID”, “post-acute sequelae of SARS CoV-2 infection (PASC)”, “long-term effects of COVID”, “chronic COVID” and so forth). Notably, a specific ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) has been developed for defining the constellation of clinical signs and symptoms that may persist after recovering from an acute SARS-CoV-2 infection, classified as “Diagnosis Code U09.9 (Post COVID-19 condition, unspecified)” [4] and, as detailed in the ICD-10-CM website, refers to the definition endorsed by WHO, summarized in Table 1. This operative description, where post-COVID and long-COVID are used almost interchangeably, requires that suggestive symptoms continue or newly develop at least 3 months after an acute SARS-CoV-2 infection, with persistence of such symptoms for not less than 2 months and with no other reasonable justifications [5]. The US Centers for Disease Control and Prevention (CDC) uses a different approach. While also failing to operate a substantial demarcation between post-COVID and long-COVID, the CDC prefer to define both conditions as persistence or newly onset of suggestive signs and symptoms after (at least) 4 weeks from an acute SARS-CoV-2 infection [6]. Thus, the timeline is considerably short compared to that endorsed by the WHO, contributing to confusion and uncertainty. To this end, recent data published by the Consortium for Clinical Characterization of COVID-19 by HER (4CE), showed the many issues emerging from the only partial overlap between these two definitions, with a rate of misclassification and/or misdiagnosis exceeding 25 % when one or the either definitions are used [7].

Table 1:

Operative definitions for classifying post-COVID conditions.

Organization Post-COVID Long-COVID
WHO Continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation Same as post-COVID (used as synonyms)
CDC Signs, symptoms, and conditions that continue or develop after initial COVID-19 or SARS-CoV-2 infection. The signs, symptoms, and conditions are present four weeks or more after the initial phase of infection Same as post-COVID (used as synonyms)
IFCC (WG & TF) Continuation of signs, symptoms or even radiologic/laboratory abnormalities of an initial SARS-CoV-2 infection, irrespective of their durationa Persistence or development of new signs, symptoms or even radiologic/laboratory abnormalities for more than 3 months after an initial SARS-CoV-2 infectiona
  1. aWith no other explainable etiology.

Understandably, the challenges arising from the inappropriate usage of the ICD-10-CM code U09.9 – reflecting poor worldwide standardization of diagnostic criteria – not only complicates diagnosis and treatment of patients with prolonged illness, but also generates a substantial impact on laboratory medicine, whereby we expect that the search for predictive and/or diagnostic biomarkers of post-COVID and/or long-COVID will exponentially grow in the nearby future [8]. We are hence providing here a tentative (operative) definition, where we suggest to define “post-COVID” as continuation of signs, symptoms or even radiologic/laboratory abnormalities of an initial SARS-CoV-2 infection, irrespective of their duration, whilst we prefer to reserve the definition of “long-COVID” to those people with persistence of signs, symptoms or even radiologic/laboratory abnormalities of an initial SARS-CoV-2 infection for more than 3 months (Table 1, Figure 1). We hope that this definition could help harmonize the classification of patients with any type of post-COVID condition for both clinical and research purposes.

Figure 1: 
Timeline of the available definitions for classifying post-COVID signs, symptoms or even laboratory abnormalities.
Figure 1:

Timeline of the available definitions for classifying post-COVID signs, symptoms or even laboratory abnormalities.


Corresponding author: Prof. Giuseppe Lippi, IFCC SARS-CoV-2 Variants Working Group, Verona, Italy; IFCC Task Force on COVID-19, Verona, Italy; and Section of Clinical Biochemistry and School of Medicine, University Hospital of Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy, Phone: 0039 045 8122970, Fax: 0039 045 8124308, E-mail:

References

1. Mattiuzzi, C, Lippi, G. Timeline analysis of clinical severity of COVID-19 in the general population. Eur J Intern Med 2023;110:97–8. https://doi.org/10.1016/j.ejim.2022.12.007.Search in Google Scholar PubMed PubMed Central

2. McVernon, J, Liberman, J. WHO keeps covid-19 a public health emergency of international concern. BMJ 2023;380:504. https://doi.org/10.1136/bmj.p504.Search in Google Scholar PubMed

3. Lippi, G, Sanchis-Gomar, F, Henry, BM. COVID-19 and its long-term sequelae: what do we know in 2023? Pol Arch Intern Med 2023;133:16402.10.20452/pamw.16402Search in Google Scholar PubMed

4. Pfaff, ER, Madlock-Brown, C, Baratta, JM, Bhatia, A, Davis, H, Girvin, A, N3C Consortium, RECOVER Consortium, et al.. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med 2023;21:58. https://doi.org/10.1186/s12916-023-02737-6.Search in Google Scholar PubMed PubMed Central

5. World Health Organization. Post COVID-19 condition (long COVID); 2022. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:∼:text=Definition,months%20with%20no%20other%20explanation [Accessed 14 Apr 2023].Search in Google Scholar

6. Long COVID or Post-COVID Conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html [Accessed 14 Apr 2023].Search in Google Scholar

7. Zhang, HG, Honerlaw, JP, Maripuri, M, Samayamuthu, MJ, Beaulieu-Jones, BR, Baig, HS, et al.. Potential pitfalls in the use of real-world data for studying long COVID. Nat Med 2023. https://doi.org/10.1038/s41591-023-02274-y [Epub ahead of print].Search in Google Scholar PubMed PubMed Central

8. Vianello, A, Guarnieri, G, Braccioni, F, Lococo, S, Molena, B, Cecchetto, A, et al.. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med 2021;60:307–16. https://doi.org/10.1515/cclm-2021-1021.Search in Google Scholar PubMed

Published Online: 2023-04-25
Published in Print: 2023-07-26

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Addressing standardized definitions of post-COVID and long-COVID
  4. Reviews
  5. The chitinases as biomarkers in immune-mediate diseases
  6. Pitfalls in the diagnosis of hematuria
  7. Opinion Papers
  8. Remote decentralized clinical trials: a new opportunity for laboratory medicine
  9. Striving for a pragmatic contribution of biomarkers results to lifelong health care
  10. IFCC Paper
  11. External quality assessment practices in medical laboratories: an IFCC global survey of member societies
  12. Guidelines and Recommendations
  13. Antibody-mediated interferences affecting cardiac troponin assays: recommendations from the IFCC Committee on Clinical Applications of Cardiac Biomarkers
  14. General Clinical Chemistry and Laboratory Medicine
  15. Evaluation of four automated clinical analyzers for the determination of total 25(OH)D in comparison to a certified LC-MS/MS
  16. Standard 20 °C freezer storage protocols may cause substantial plasma renin cryoactivation
  17. Lower accuracy of testosterone, cortisol, and free T4 measurements using automated immunoassays in people undergoing hemodialysis
  18. Multicenter study to compare the diagnostic performance of CLIA vs. FEIA transglutaminase IgA assays for the diagnosis of celiac disease
  19. Imprecision remains to be improved in the measurement of serum cystatin C with heterogeneous systems
  20. Analytical validation of the modified Westergren method on the automated erythrocyte sedimentation rate analyzer CUBE 30 touch
  21. Reference Values and Biological Variations
  22. Systematic review and meta-analysis of within-subject and between-subject biological variation data of coagulation and fibrinolytic measurands
  23. Biological variation estimates for spot urine analytes and analyte/creatinine ratios in 33 healthy subjects
  24. Short-term biological variation of plasma uracil in a Caucasian healthy population
  25. Cardiovascular Diseases
  26. Elevated Hemolysis Index is associated with higher risk of cardiovascular diseases
  27. Infectious Diseases
  28. Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay
  29. Pre-analytical considerations in the development of a prototype SARS-CoV-2 antigen ARCHITECT automated immunoassay
  30. SARS CoV-2 spike protein-guided exosome isolation facilitates detection of potential miRNA biomarkers in COVID-19 infections
  31. Monocyte distribution width alterations and cytokine storm are modulated by circulating histones
  32. Letters to the Editor
  33. Letter to the Editor regarding the article by Wayne J. Dimech et al. Time to address quality control processes applied to antibody testing for infectious diseases. Clin Chem Lab Med 2023; 61(2):205–212
  34. Response to Tony Badrick regarding “Letter to the Editor regarding the article by Wayne J. Dimech et al. Time to address quality control processes applied to antibody testing for infectious diseases. Clin Chem Lab Med 2023; 61(2):205–212 by”
  35. Monocyte distribution width (MDW) as a reliable biomarker for urosepsis
  36. A consistency analysis of common biochemical tests in arterial blood and venous blood of critically ill patients
  37. Test results comparison: is the S-Monovette® Lithium-Heparin Gel+ a suitable replacement for the S-Monovette® Lithium-Heparin Gel on Alinity Abbott®?
  38. Analytical performance of Abbott’s ARCHITECT and Alinity TSH-receptor antibody (TRAb) assays
  39. Cis-AB showing discrepant results across different automated and manual methods: a case report and review of the literature
  40. A graphical tool to investigate method validation
  41. Live lab-monitor; a customizable HTML-based and systems independent, real-time laboratory overview screen
  42. Congress Abstracts
  43. 61st National Congress of the Hungarian Society of Laboratory Medicine
  44. 9th Annual Meeting of the Austrian Society for Laboratory Medicine and Clinical Chemistry (ÖGLMKC)
Downloaded on 24.7.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2023-0390/html
Scroll to top button